Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports

INTRODUCTION: Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion ther...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore)
Main Authors: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Masahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Saito, Yu, Imura, Satoru, Bando, Yoshimi, Shimada, Mitsuo, Takayama, Tetsuji
Format: Artigo
Language:Inglês
Published: Lippincott Williams & Wilkins 2020
Subjects:
5700
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571946/
https://ncbi.nlm.nih.gov/pubmed/33080748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000022782
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items